External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors.

Autor: Morote J; Department of Urology, Vall d´Hebron Hospital, Barcelona, Spain. juan.morote@vallhebron.cat.; Department of Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain. juan.morote@vallhebron.cat., Borque-Fernando Á; Department of Urology, Hospital Universitario Miguel Servet, IIS-Aragon, Zaragoza, Spain., Esteban LM; Department of Applied Mathematics, Escuela Universitaria Politécnica La Almunia, Universidad de Zaragoza, Zaragoza, Spain., Picola N; Department of Urology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain., Muñoz-Rodriguez J; Department of Urology, Hospital Universitari Parc Taulí, Sabadell, Spain., Paesano N; Department of Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain.; Clínica Creu Blanca, Barcelona, Spain., Ruiz-Plazas X; Department of Urology, Hospital Universitari Joan XXIII, Tarragona, Spain., Muñoz-Rivero MV; Department of Urology, Hospital Universitari Arnau de Vilanova, Lleida, Spain., Celma A; Department of Urology, Vall d´Hebron Hospital, Barcelona, Spain., Manuel GG; Department of Urology, Hospital Universitari Josep Trueta, Girona, Spain., Miró B; Unit of Statistics and Bioinformatics, Vall d´Hebron Research Institute, Barcelona, Spain., Abascal JM; Department of Urology, Parc de Salut Mar, Barcelona, Spain., Servian P; Department of Urology, Hospital Germans Trias i Pujol, Badalona, Spain.
Jazyk: angličtina
Zdroj: World journal of urology [World J Urol] 2024 Jul 10; Vol. 42 (1), pp. 393. Date of Electronic Publication: 2024 Jul 10.
DOI: 10.1007/s00345-024-05092-0
Abstrakt: Purpose: To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI).
Materials and Methods: A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2.
Results: The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783-0.842) and 0.849 (0.806-0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users.
Conclusions: The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: